North Augusta, South Carolina – 3rd August 2026
Today, we are pleased to announce that CordenPharma has successfully completed the acquisition of AmbioPharm, representing a significant milestone in our journey as a leading peptide CDMO.
With the closing of the transaction, our facilities in North Augusta, South Carolina (USA) – to become CordenPharma South Carolina – and Shanghai (China) – to become CordenPharma Shanghai – will be integrated into CordenPharma’s global manufacturing footprint over the coming months, enhancing our ability to support complex peptide programs across development, clinical supply, and commercial manufacturing.
In South Carolina, AmbioPharm adds expanded downstream capabilities, including enhanced purification and lyophilization, with additional investment in upstream capacity planned. In Shanghai, we bring a cutting-edge facility to CordenPharma’s network, adding significant upstream peptide manufacturing capacity.
Greater Geographic Reach with Increased Supply Chain Resilience
By adding a second U.S. peptide facility and a new presence in Asia, the acquisition reinforces CordenPharma’s Peptides Platform and enhances our combined global manufacturing network, providing customers with increased geographic flexibility and supply options that help ensure reliable delivery across all stages of the peptide product lifecycle.
In the US, CordenPharma’s Colorado site complements the South Carolina facility with expanded R&D capacity and large-scale commercial expertise, creating fully U.S.-based peptide API supply.
In Europe, CordenPharma’s robust GMP peptide development facility in Frankfurt, Germany, alongside the new up- and downstream capabilities in Shanghai, help support more regionally aligned supply models across three continents.
Enhanced Value for Our Customers
Our newly-combined customer base will directly benefit from:
- Expanded capacity and technical capabilities for complex peptide APIs
- Greater flexibility in manufacturing location and scale-up pathways
- Increased supply chain resilience
- Accelerated development and commercialization timelines through our integrated expertise
Overall, our combined peptide platforms deliver a more flexible, scalable, and reliable path from early development through global commercialization.
The acquisition also strengthens CordenPharma’s integrated offering, supporting seamless end-to-end supply from drug substance to drug products, including sterile injectable and oral solid dosage forms, with expertise in oral peptide delivery.
Looking Ahead
With the successful closing of the transaction, the AmbioPharm sites will be fully integrated into CordenPharma’s global facility network and operate under the CordenPharma brand, creating an expanded global team of ~3500 employees.
We are pleased to join our new CordenPharma colleagues and look forward to building the future of peptide therapeutics together, with even greater value for our combined customer base and their patients worldwide.
